NI+

FDA proposes NAC supplement rule amid drug preclusion debate

"This action is the FDA’s first use of our rulemaking authority described in the exclusion provision of the dietary supplement definition, and NAC would be the first ingredient listed under this new regulation," FDA wrote.
"This action is the FDA’s first use of our rulemaking authority described in the exclusion provision of the dietary supplement definition, and NAC would be the first ingredient listed under this new regulation," FDA wrote. (Getty Images)

The U.S. Food and Drug Administration (FDA) proposed a rule on Nov. 16 that would allow N-acetylcysteine (NAC) to be marketed as a dietary supplement, a move intended to resolve years of uncertainty over the ingredient’s status under the drug preemption provision.

The proposal marks the first time the agency has used its authority under Section 201(ff)(3)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) to create an exception for an ingredient that would otherwise be excluded from the dietary supplement definition.

Industry associations welcomed the proposal but raised questions about whether the FDA would establish a similar process for other ingredients affected by drug preclusion.

FDA proposes formal NAC exception

Under the proposed rule, NAC would become the first ingredient covered by a new regulation titled “Dietary Ingredients Not Excluded from the Dietary Supplement Definition.”

The FDA previously determined that NAC was excluded from the dietary supplement definition because it had been approved as a drug before being marketed as a supplement.

In March 2022, the agency denied citizen petitions from the Council for Responsible Nutrition (CRN) and Natural Products Association (NPA) seeking to establish that NAC was not excluded from the dietary supplement definition.

Explore related questions

The FDA, however, left unresolved an alternative request in NPA’s petition asking the agency to undertake rulemaking to allow NAC in supplements.

In August 2022, the FDA adopted an enforcement discretion policy allowing certain NAC-containing products to remain on the market while it considered the issue.

An FDA spokesperson attributed the agency’s decision to pursue formal rulemaking to NAC’s safety profile and the proposal’s expected limited impact on pharmaceutical development.

“The FDA is proposing this rule based on the safety profile of N-acetyl-L-cysteine (NAC) and the minimal, if any, impact this rule is likely to have on NAC drug development,” the spokesperson said.

In its Nov. 16 constituent update, the FDA also cited its safety assessment of NAC.

“The FDA undertook a comprehensive review and did not identify any safety concerns with the use of NAC in or as a dietary supplement,” the agency stated.

The FDA is publishing a comprehensive safety review to support the proposal. According to the agency, NAC-containing products marketed as dietary supplements have been sold in the United States for more than 30 years.

The agency said it would continue its existing enforcement discretion policy during the rulemaking process. However, the FDA spokesperson emphasized that the policy does not make NAC supplements lawfully marketed products.

“While the FDA intends to continue our posture of enforcement discretion with respect to the sale and distribution of NAC-containing products while we work through the rulemaking process, these products would not be lawfully marketed until the effective date of any final rule,” the spokesperson said.

The proposal is open for public comment for 60 days.

If finalized, the rule would permit NAC-containing products to be marketed as dietary supplements, provided they meet other applicable requirements under the FD&C Act.

NPA welcomes regulatory resolution

The Natural Products Association (NPA), whose earlier petition included a request for the rulemaking approach now being proposed, welcomed the announcement.

“This is all direct result of NPA, right? It was our citizens petition,” said Daniel Fabricant, PhD, president and CEO of NPA. “So kudos to NPA, our board, our council.”

Fabricant said the agency’s decision to use its existing statutory authority demonstrated that disputes over drug preclusion could be addressed without changes to the law.

“It shows that these disputes can be resolved, that the law works and works well,” he said.

He pointed to NPA’s work on nicotinamide mononucleotide (NMN) and emphasized the importance of pursuing specific regulatory solutions rather than focusing solely on disagreements with the FDA.

As to whether the NAC rulemaking approach could apply to other ingredients, including NMN, the FDA spokesperson referred to the agency’s citizen petition response.

“As described in this citizen petition response, beta-nicotinamide mononucleotide (NMN) is not excluded from the dietary supplement definition,” the spokesperson said.

Rend Al-Mondhiry, partner and co-chair of the regulatory group at Amin Wasserman Gurnani LLP, also noted the significance of the agency’s use of its statutory authority.

“This is a significant development for the supplement industry,” she told NI.

“It’s the first time FDA is exercising its authority under Section 201(ff)(3)(B) of the FD&C Act to establish a regulatory pathway for ingredients that would otherwise be excluded from the dietary supplement definition.”

Al-Mondhiry said the proposal could have broader implications for other ingredients facing drug preclusion issues. She also noted that the FDA’s shift from enforcement discretion to a formal regulatory process could allow other qualifying ingredients to be marketed as supplements or included in conventional foods, where appropriate.

Industry seeks broader drug preclusion reform

The Council for Responsible Nutrition (CRN) welcomed the proposal but said the FDA had not provided a clear process for considering other ingredients under the same authority.

“We welcome FDA’s proposal to establish a regulatory pathway that would provide certainty for NAC,” said Steve Mister, president and CEO of CRN in a press release.

“But without a clear framework for how other ingredients can be added, the industry is left with many of the same uncertainties that have persisted for years.”

CRN filed a separate citizen petition in May 2023 seeking changes to the agency’s interpretation of drug preclusion and submitted additional arguments in March 2025. The FDA denied that petition in September 2025.

The association continues to seek clarification on the agency’s reliance on confidential investigational new drug application dates, what constitutes substantial clinical investigations and whether differences in dosage, route of administration and intended use should affect drug preclusion determinations.

“FDA has opened the door for other ingredients to be considered, but it has not explained how manufacturers can walk through it,” Mister said.

The American Herbal Products Association (AHPA) also supported the proposal while calling for changes to the broader statutory framework.

“Formal action from FDA to recognize the lawful status of NAC is welcome, and we appreciate the agency’s utilizing of its statutory authority to resolve this uncertainty,” Graham Rigby, president and CEO of AHPA told NI.

“However, the FD&C Act’s drug preclusion provision remains fundamentally imbalanced, creating unnecessary unpredictability for responsible companies and limiting consumer access to safe dietary ingredients.”

Both CRN and AHPA pointed to the Dietary Supplement Innovation Act as a legislative approach to addressing drug preclusion.

Rigby added that securing comprehensive legislative reform, including through the proposed legislation, would be a priority for AHPA in 2027.

CRN confirmed it would review the FDA’s proposal and submit comments while continuing to advocate for clearer standards governing when drug preclusion applies.